Why December's holiday rush could endanger your heart health
Why December's holiday rush could endanger your heart health
Why December's holiday rush could endanger your heart health
The last week of December sees more heart attack deaths than any other time of year. While exact figures for this period remain unclear, Germany records around 44,000 fatal heart attacks annually. Doctors warn that holiday pressures and lifestyle changes may be contributing factors.
Stress levels often rise during the festive season, with increased hormones posing risks for those with heart conditions. Rich holiday foods and alcohol can also disrupt heart rhythms, sometimes leading to atrial fibrillation. Many people ignore early warning signs like chest pain or breathlessness, delaying critical treatment.
Dr. Sanders has advised moderation in celebrations to lower health dangers. She emphasised that rapid medical response is vital for heart attacks and strokes, as delays worsen outcomes. The phrase 'time is muscle' highlights how quickly heart tissue deteriorates without intervention, while 'time is brain' underscores the urgency for stroke victims.
Experts urge anyone with chest pain, breathing difficulties, or a family history of heart disease to seek help immediately. Recognising symptoms early and acting fast can save lives. With holiday risks in mind, moderation and awareness remain key to staying safe.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?